Journal of Antivirals & Antiretrovirals
Open Access

Triple infection among people living with HIV (PLWH): Implication in antiretroviral therapy

International Conference and Exhibition on VIROLOGY

5-7 September 2011 Baltimore, USA

Taiwo. M. Oyesile Balogun, A.Adewolu, S Emmanuel and O Ojerinde

Scientific Tracks Abstracts: JAA

Abstract :

Background: Hepatitis B and C viruses (HBV and HCV) co infection among HIV infected individuals is common and has serious clinical and therapeutic implications. Patients co infected with both HIV and hepatitis progress faster to cirrhosis and hepatocellular carcinoma than those with HIV monoinfection. Infection with hepatitis B or C may accelerate the progression of HIV disease. Hepatitis co infection among PLWH who are on antiretroviral therapy increases the risk of hepatotoxicity. In Nigeria, the prevalence of HBVand HCV among PLWH has been documented high. Th e aim of this study is to determine the prevalence of hepatitis co infection among PLWH. Methods: Sera from HIV confi rmed patients and healthy blood donor controls were tested for HBV and HCV markers. Results: Dual presence of HBVand HCV was observed in 4(3.9%) of HIV infected while 29(28.4%) and 15(14.7%) were positive for HBV and HCV respectively. HIV negative healthy blood donors controls have HBV and HCV prevalence of 6.0% and 0.8% respectively with no dual infection.observed Conclusion: HIV positive patients are more likely to have hepatitis co infections. Recommendations: To reduce the risks of antiretroviral drug hepatotoxicity, all PLWH need to have their hepatitis status confi rmed before drug initiation. Th is would guide appropriate choice of drug combinations. Emphasis would be on prevention for the hepatitis seronegative PLWH